{"disease":{"id":"schizophrenia","name":"Schizophrenia","therapeutic_area":"Psychiatry","data":{"aiSummary":"The treatment landscape for schizophrenia primarily involves antipsychotic medications, with a shift towards long-acting injectables (LAIs) to improve adherence. Recent advances include the development of novel antipsychotics with different mechanisms of action, such as SEP-363856. The pipeline includes various agents targeting different receptors and pathways, including dopamine and serotonin, with a focus on improving efficacy and reducing side effects. Future directions involve personalized treatment approaches based on genetic and biomarker profiles.","drug_count":11,"description":"Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. It is characterized by distorted perceptions, disorganized thinking, and a range of other symptoms. The pathophysiology involves complex interactions of genetic, environmental, and neurochemical factors, particularly involving dopamine and glutamate pathways. Treatment primarily focuses on antipsychotic medications, along with psychosocial therapies.","subtype_count":13},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.964Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":45,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"paliperidone-palmitate","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invega Sustenna","generic_name":"PALIPERIDONE PALMITATE","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Atypical Antipsychotic","quality_score":75,"revenue":"3800","mechanism":"Invega Sustenna works by blocking a specific channel in the brain that helps regulate electrical activity."},{"drug_id":"cariprazine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vraylar","generic_name":"CARIPRAZINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":66,"revenue":"3267","mechanism":"Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior."},{"drug_id":"aripiprazole","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"aripiprazole","indication_name":"Agitation associated with Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abilify","generic_name":"aripiprazole","company_name":"Generic (originally Otsuka/BMS)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Third-generation antipsychotic (D2 partial agonist)","quality_score":63,"revenue":"3000","mechanism":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it."},{"drug_id":"brexpiprazole","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rexulti","generic_name":"BREXPIPRAZOLE","company_name":"Otsuka","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":60,"revenue":"1400","mechanism":""},{"drug_id":"rexulti","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rexulti","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor","drug_class":"","quality_score":24,"revenue":"1400","mechanism":null},{"drug_id":"lumateperone","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caplyta","generic_name":"LUMATEPERONE","company_name":"Intra-Cellular","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":65,"revenue":"900","mechanism":"Caplyta works by binding to the 5-hydroxytryptamine receptor 2A, which helps to regulate dopamine and serotonin levels in the brain."},{"drug_id":"aripiprazole-lauroxil","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aristada","generic_name":"ARIPIPRAZOLE LAUROXIL","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"","quality_score":63,"revenue":"500","mechanism":"Aristada works by blocking dopamine receptors in the brain to help regulate abnormal thought and behavior patterns."},{"drug_id":"olanzapine","indication_name":"Agitation associated with Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":38,"revenue":"300","mechanism":null},{"drug_id":"olanzapine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":38,"revenue":"300","mechanism":null},{"drug_id":"abilify","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chlorpromazine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thorazine","generic_name":"chlorpromazine","company_name":"Generic (originally Rhône-Poulenc/Sanofi)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Sphingomyelin phosphodiesterase, 5-hydroxytryptamine receptor 1E","drug_class":"Typical antipsychotic (first-generation, phenothiazine)","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"blonanserin","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lonasen","generic_name":"BLONANSERIN","company_name":"Dainippon Sumitomo Pharma Co., Ltd.","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"blonanserin","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"sertindole","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zerdol","generic_name":"SERTINDOLE","company_name":"H. Lundbeck A/S","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2C","drug_class":"sertindole","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"thiothixene","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Navane","generic_name":"THIOTHIXENE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Typical Antipsychotic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"quetiapine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"samidorphan","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":60,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"asenapine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphris","generic_name":"ASENAPINE","company_name":"Hisamitsu","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2C","drug_class":"Atypical Antipsychotic [EPC]","quality_score":67,"revenue":null,"mechanism":"Saphris works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2C."},{"drug_id":"mesoridazine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thioridazine-2-Sulfoxide","generic_name":"MESORIDAZINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Phenothiazine","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"carfenazine","indication_name":"Chronic schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carphenazin","generic_name":"carfenazine","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"mosapramine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cremin","generic_name":"MOSAPRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor","drug_class":"mosapramine","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"amisulpride","indication_name":"Chronic schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Barhemsys","generic_name":"AMISULPRIDE","company_name":"Acacia","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Dopamine-2 Receptor Antagonist [EPC]","quality_score":57,"revenue":null,"mechanism":"Barhemsys works by blocking dopamine receptors in the brain."},{"drug_id":"clozapine","indication_name":"Suicidal Behavior in Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clozaril","generic_name":"CLOZAPINE","company_name":"Jazz Pharmaceuticals","drug_phase":"marketed","molecular_target":"D2, 5-HT2A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":69,"revenue":null,"mechanism":"Clozapine's efficacy in schizophrenia may be due to its antagonism of D2 and 5-HT2A receptors."},{"drug_id":"clozapine","indication_name":"Treatment-Resistant Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clozaril","generic_name":"CLOZAPINE","company_name":"Jazz Pharmaceuticals","drug_phase":"marketed","molecular_target":"D2, 5-HT2A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":69,"revenue":null,"mechanism":"Clozapine's efficacy in schizophrenia may be due to its antagonism of D2 and 5-HT2A receptors."},{"drug_id":"fluphenazine-enanthate","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Moditen Enanthate","generic_name":"FLUPHENAZINE ENANTHATE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Phenothiazine","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"clozaril","indication_name":"Suicidal Behavior in Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clozaril","company_name":"Dong Wha Pharmaceutical Co. Ltd.","drug_phase":"phase_1","molecular_target":"Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E","drug_class":"","quality_score":12,"revenue":null,"mechanism":""},{"drug_id":"clozaril","indication_name":"Treatment-Resistant Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clozaril","company_name":"Dong Wha Pharmaceutical Co. Ltd.","drug_phase":"phase_1","molecular_target":"Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E","drug_class":"","quality_score":12,"revenue":null,"mechanism":""},{"drug_id":"flupenthixol","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flupenthixol","company_name":"National Institute on Drug Abuse (NIDA)","drug_phase":"phase_2","molecular_target":"D(1B) dopamine receptor, D(4) dopamine receptor, Solute carrier family 22 member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperidone","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Risperdal","generic_name":"risperidone","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"Atypical Antipsychotic [EPC]","quality_score":58,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder."},{"drug_id":"ziprasidone","indication_name":"Agitation associated with Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":55,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"ziprasidone","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Geodon","generic_name":"ziprasidone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical antipsychotic (second-generation)","quality_score":55,"revenue":null,"mechanism":"Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class."},{"drug_id":"caplyta","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Caplyta","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"mesoridazine-besylate","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MESORIDAZINE BESYLATE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A","drug_class":"Typical antipsychotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"haloperidol","indication_name":"Chronic schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Haldol","generic_name":"haloperidol","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Typical Antipsychotic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"haloperidol","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Haldol","generic_name":"haloperidol","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Typical Antipsychotic [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"fluspirilene","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Redeptin","generic_name":"FLUSPIRILENE","company_name":"","drug_phase":"discontinued","molecular_target":"D(2) dopamine receptor","drug_class":"fluspirilene","quality_score":null,"revenue":null,"mechanism":"Redeptin works by blocking dopamine receptors in the brain."},{"drug_id":"oxypertine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxypertin","generic_name":"OXYPERTINE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxypertine","quality_score":null,"revenue":null,"mechanism":"Oxypertine is thought to work by modulating neurotransmitter activity in the brain."},{"drug_id":"lurasidone","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Latuda","generic_name":"LURASIDONE","company_name":"Sunovion Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":80,"revenue":null,"mechanism":"Latuda works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to regulate mood and reduce symptoms of psychosis."},{"drug_id":"iloperidone","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fanapt","generic_name":"ILOPERIDONE","company_name":"Vanda Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":75,"revenue":null,"mechanism":"Fanapt works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to reduce symptoms of schizophrenia."},{"drug_id":"perphenazine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilafon","generic_name":"PERPHENAZINE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Phenothiazine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prochlorperazine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Compazine","generic_name":"PROCHLORPERAZINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Phenothiazine","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"chlorprothixene","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taractan","generic_name":"CHLORPROTHIXENE","company_name":"Roche","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"chlorprothixene","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"loxapine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adasuve","generic_name":"LOXAPINE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"loxapine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"molindone","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Moban","generic_name":"MOLINDONE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Typical Antipsychotic","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"trifluoperazine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Stelazine","generic_name":"TRIFLUOPERAZINE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Phenothiazine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"fluphenazine-decanoate","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prolixin Decanoate","generic_name":"FLUPHENAZINE DECANOATE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Phenothiazine","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"fluphenazine","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prolixin","generic_name":"FLUPHENAZINE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Phenothiazine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"haloperidol-decanoate","indication_name":"Chronic schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Haldol","generic_name":"HALOPERIDOL DECANOATE","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Typical Antipsychotic","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"seroquel","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"risperdal","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Risperdal","company_name":"Ohio State University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"serdolect","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Serdolect","company_name":"University of Aarhus","drug_phase":"phase_1","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Agitation associated with Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fazaclo","indication_name":"Suicidal Behavior in Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fazaclo","company_name":"Manhattan Psychiatric Center","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"samidorphan","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lybalvi","generic_name":"SAMIDORPHAN","company_name":"Alkermes Inc","drug_phase":"marketed","molecular_target":"Mu-type opioid receptor","drug_class":"Atypical Antipsychotic [EPC]","quality_score":60,"revenue":null,"mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain."},{"drug_id":"fazaclo","indication_name":"Treatment-Resistant Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fazaclo","company_name":"Manhattan Psychiatric Center","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lurasidone","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Latuda","generic_name":"LURASIDONE","company_name":"Sunovion Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":80,"revenue":null,"mechanism":"Latuda works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to regulate mood and reduce symptoms of psychosis."},{"drug_id":"molindone","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Moban","generic_name":"MOLINDONE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Typical Antipsychotic","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"samidorphan-l-malate","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SAMIDORPHAN L-MALATE","company_name":"","drug_phase":"marketed","molecular_target":"dopamine and serotonin type 2 (5HT2) receptors, opioid receptors","drug_class":"Atypical Antipsychotic [EPC]","quality_score":55,"revenue":null,"mechanism":"Olanzapine's efficacy may be due to dopamine and serotonin type 2 antagonism, while samidorphan acts through opioid receptor antagonism."},{"drug_id":"paliperidone","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PALIPERIDONE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Atypical Antipsychotic [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"prochlorperazine-maleate","indication_name":"Schizophrenia Treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PROCHLORPERAZINE MALEATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"flupentixol","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluanxol","generic_name":"FLUPENTIXOL","company_name":"","drug_phase":"discontinued","molecular_target":"Histamine H1 receptor","drug_class":"High Risk QT Prolonging Agents","quality_score":null,"revenue":null,"mechanism":"Flupentixol works by blocking the histamine H1 receptor, which helps regulate various physiological processes including mood and cognition."},{"drug_id":"zuclopenthixol","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clopixol","generic_name":"ZUCLOPENTHIXOL","company_name":"","drug_phase":"discontinued","molecular_target":"5-hydroxytryptamine receptor 6","drug_class":"High Risk QT Prolonging Agents","quality_score":null,"revenue":null,"mechanism":"Clopixol works by blocking the 5-hydroxytryptamine receptor 6, which helps to regulate mood and reduce symptoms of schizophrenia."},{"drug_id":"sulpiride","indication_name":"Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulpirid","generic_name":"SULPIRIDE","company_name":"","drug_phase":"discontinued","molecular_target":"Carbonic anhydrase 6","drug_class":"High Risk QT Prolonging Agents","quality_score":null,"revenue":null,"mechanism":"Sulpiride works by blocking the action of carbonic anhydrase 6, an enzyme that helps regulate the balance of acid and base in the brain."},{"drug_id":"abilify","indication_name":"Agitation associated with Schizophrenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abilify","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":66,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06115200","title":"Norwegian Adult Mental Health Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Helse Stavanger HF","has_results":false},{"nct_id":"NCT07005245","title":"Survey on the Reproductive and Child-Rearing Situations of Patients With Severe Mental Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":77145,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06641726","title":"Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Akrivia Health","has_results":false},{"nct_id":"NCT06370793","title":"Ningbo Schizophrenia Cohort","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":26899,"lead_sponsor_name":"Ningbo University","has_results":false},{"nct_id":"NCT06818227","title":"MonPsy&Moi: A Digital Platform for Collecting Patient-Reported Experience and Outcome Measures in Psychiatry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":23660,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT04655287","title":"A Register Study of Effects Following Local Variation in Rates of Involuntary Care","phase":"","overall_status":"COMPLETED","enrollment_count":21759,"lead_sponsor_name":"University Hospital, Akershus","has_results":false},{"nct_id":"NCT05206734","title":"Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health","phase":"","overall_status":"COMPLETED","enrollment_count":19469,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT04002258","title":"Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":10363,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT02451670","title":"Reducing Cardiovascular Risk in Adults With Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":10347,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT00001486","title":"Genetic Study of Schizophrenia","phase":"","overall_status":"COMPLETED","enrollment_count":4914,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT00001192","title":"Neuropsychological Evaluation of Psychiatric and Neurological Patients","phase":"","overall_status":"COMPLETED","enrollment_count":4300,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT00001246","title":"Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4274,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT00004571","title":"Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers","phase":"","overall_status":"COMPLETED","enrollment_count":3273,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT01819818","title":"A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients","phase":"","overall_status":"COMPLETED","enrollment_count":3267,"lead_sponsor_name":"Janssen Korea, Ltd., Korea","has_results":false},{"nct_id":"NCT04432688","title":"The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients","phase":"","overall_status":"COMPLETED","enrollment_count":3192,"lead_sponsor_name":"Sumitomo Pharma (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04001439","title":"FEcal Microbiota Transplantation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":3088,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT03790085","title":"Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":2700,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT00001260","title":"Brain Tissue Collection for Neuropathological Studies","phase":"","overall_status":"TERMINATED","enrollment_count":2161,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT03451734","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Central South University","has_results":false},{"nct_id":"NCT06123897","title":"Establishing a Clinical Database and Biobank for Schizophrenia：A Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Central South University","has_results":false},{"nct_id":"NCT00460512","title":"An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1814,"lead_sponsor_name":"Janssen-Cilag International NV","has_results":false},{"nct_id":"NCT03656770","title":"Measuring Beliefs and Norms About Persons With Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":1782,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT00001198","title":"Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia","phase":"","overall_status":"TERMINATED","enrollment_count":1556,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT05498571","title":"Risk Prediction Model of Cardiovascular Events in Patients With Schizophrenia","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT07379827","title":"Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03740139","title":"The Police-Mental Health Linkage System","phase":"NA","overall_status":"COMPLETED","enrollment_count":1405,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT03451630","title":"Integrated Care (IC) Models for Patient-Centered Outcomes","phase":"NA","overall_status":"COMPLETED","enrollment_count":1400,"lead_sponsor_name":"University of Pittsburgh","has_results":true},{"nct_id":"NCT00001921","title":"Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings","phase":"","overall_status":"COMPLETED","enrollment_count":1386,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT05211947","title":"A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1356,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05603104","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1254,"lead_sponsor_name":"Dr. Inge Winter","has_results":false},{"nct_id":"NCT00212784","title":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1225,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT02845440","title":"Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness","phase":"NA","overall_status":"COMPLETED","enrollment_count":1165,"lead_sponsor_name":"Massachusetts General Hospital","has_results":true},{"nct_id":"NCT00137280","title":"Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1067,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT00001258","title":"Studies of Frontal Lobe Brain Functioning in Schizophrenia","phase":"","overall_status":"COMPLETED","enrollment_count":1039,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT03386851","title":"Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder","phase":"","overall_status":"COMPLETED","enrollment_count":1030,"lead_sponsor_name":"Korea Otsuka Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06657430","title":"A Study on the Preference of Risperidone Dosage Forms","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT03345342","title":"A Study of Paliperidone Palmitate 6-Month Formulation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":841,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT04055181","title":"Influence of rTMS on Symptoms and Cognitive Function in Patients With Psychiatric Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Beijing HuiLongGuan Hospital","has_results":false},{"nct_id":"NCT03289026","title":"Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":770,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT01412060","title":"A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":765,"lead_sponsor_name":"Forest Laboratories","has_results":true},{"nct_id":"NCT03510325","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":762,"lead_sponsor_name":"Shanghai Mental Health Center","has_results":false},{"nct_id":"NCT01104792","title":"Long-term Study of Cariprazine in Patients With Schizophrenia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":752,"lead_sponsor_name":"Forest Laboratories","has_results":true},{"nct_id":"NCT00694707","title":"Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":732,"lead_sponsor_name":"Forest Laboratories","has_results":true},{"nct_id":"NCT01129882","title":"An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":709,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT01914393","title":"Pediatric Open-Label Extension Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":702,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":true},{"nct_id":"NCT05090644","title":"Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on the Isolation of Gene Polymorphism in Schizophrenia in People of the Kazakh Ethnic Group","phase":"","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"Asfendiyarov Kazakh National Medical University","has_results":false},{"nct_id":"NCT05443724","title":"A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03975400","title":"Using Digital Media Advertising to Reduce the Duration of Untreated Psychosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":698,"lead_sponsor_name":"Northwell Health","has_results":true},{"nct_id":"NCT05693935","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":675,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D LLC","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}